Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdict

With the FDA expected to weigh in on its kidney transplant drug, imlifidase, shortly before year-end, Hansa Biopharma is mulling over its stock listing options in the U.S.